Forest Labs to present cariprazine results from a Phase 3 trial

theflyonthewall.com

Forest Laboratories announced it will be presenting data on cariprazine at the American College of Neuropsychopharmacology Annual Meeting scheduled December 2-6, in Hollywood, FL. Forest Laboratories, Inc recently submitted a New Drug Application to the U.S. Food and Drug Administration, FDA, for cariprazine for the treatment of schizophrenia and the acute treatment of manic or mixed episodes associated with Bipolar I disorder.

Rates

View Comments (0)